Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to \<24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.

Key facts

Study ID
NCT04235140
Run by
Vertex Pharmaceuticals Incorporated
People needed
52
Starts
2020-02-24
Expected to finish
2023-08-22
Last updated by the study team
2024-09-19

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.